{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:42:32Z","timestamp":1783942952598,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jns.2017.10.037","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T11:30:52Z","timestamp":1509967852000},"page":"118-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy"],"prefix":"10.1016","volume":"383","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-7486","authenticated-orcid":false,"given":"Josep","family":"Gamez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Salvado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Casellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2017.10.037_bb0005","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00003081-198309000-00010","article-title":"Myasthenia gravis","volume":"26","author":"Plauch\u00e9","year":"1983","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.jns.2017.10.037_bb0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1212\/WNL.52.3.447","article-title":"Course and treatment of myasthenia gravis during pregnancy","volume":"52","author":"Batocchi","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0301-2115(99)00197-9","article-title":"Myasthenia gravis and pregnancy","volume":"89","author":"Daskalakis","year":"2000","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jns.2017.10.037_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0301-2115(02)00051-9","article-title":"Myasthenia gravis in pregnancy: report on 69 cases","volume":"104","author":"Djelmis","year":"2001","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jns.2017.10.037_bb0025","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/01.WNL.0000082725.21444.EC","article-title":"Myasthenia gravis: consequences for pregnancy, delivery, and the newborn","volume":"61","author":"Hoff","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.annfar.2004.01.014","article-title":"Myasthenia gravis, pregnancy and delivery: a series of ten cases","volume":"23","author":"Chabert","year":"2004","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"10.1016\/j.jns.2017.10.037_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-2004-829590","article-title":"The management of myasthenia gravis in pregnancy","volume":"24","author":"Ciafaloni","year":"2004","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0040","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1468-1331.2004.00900.x","article-title":"Asymptomatic myasthenia gravis influences pregnancy and birth","volume":"11","author":"Hoff","year":"2004","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2005.01.002","article-title":"Myasthenia gravis: management issues during pregnancy","volume":"121","author":"Ferrero","year":"2005","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.jns.2017.10.037_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1468-1331.2006.01538.x","article-title":"Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care","volume":"14","author":"Hoff","year":"2007","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2474-5-42","article-title":"Myasthenia gravis and pregnancy: clinical implications and neonatal outcome","volume":"5","author":"T\u00e9llez-Zenteno","year":"2004","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.jns.2017.10.037_bb0060","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1586\/14737175.8.6.979","article-title":"Myasthenia gravis during pregnancy","volume":"8","author":"Ferrero","year":"2008","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jns.2017.10.037_bb0065","first-page":"1346","article-title":"Myasthenia gravis during pregnancy","volume":"58","author":"Chaudhry","year":"2012","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.jns.2017.10.037_bb0070","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/GRF.0b013e31828e92c0","article-title":"Myasthenia gravis and pregnancy","volume":"56","author":"Varner","year":"2013","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.jns.2017.10.037_bb0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jnnp-2013-305777","article-title":"Myasthenia gravis and pregnancy: pressing time for best practice guidelines","volume":"85","author":"Maddison","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.10.037_bb0080","first-page":"115","article-title":"Pregnancy and myasthenia gravis","volume":"20","author":"Massey","year":"2014","journal-title":"Continuum"},{"key":"10.1016\/j.jns.2017.10.037_bb0085","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2017.10.037_bb0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mus.24556","article-title":"Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why?","volume":"52","author":"Ohlraun","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2017.10.037_bb0095","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mus.25095","article-title":"Myasthenia gravis in pregnancy - experience of a Portuguese center","volume":"54","author":"Braga","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2017.10.037_bb0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/15513815.2016.1164773","article-title":"Neonatal outcome in pregnancies with autoimmune myasthenia gravis","volume":"35","author":"Jovandaric","year":"2016","journal-title":"Fetal Pediatr. Pathol."},{"key":"10.1016\/j.jns.2017.10.037_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/01443610601016842","article-title":"Myasthenia gravis and pregnancy","volume":"27","author":"Kalidindi","year":"2007","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.jns.2017.10.037_bb0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejcts.2005.11.022","article-title":"Effect of pregnancy and birth on the course of myasthenia gravis before or after transsternal radical thymectomy","volume":"29","author":"Roth","year":"2006","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.jns.2017.10.037_bb0115","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/WNL.54.9.1873","article-title":"Pyridostigmine-induced microcephaly","volume":"54","author":"Niesen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0120","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/beog.2001.0234","article-title":"Drugs in pregnancy. Anticonvulsants and drugs for neurological disease","volume":"15","author":"Lowe","year":"2001","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jns.2017.10.037_bb0125","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1212\/WNL.56.11.1606","article-title":"Pyridostigmine-induced microcephaly","volume":"56","author":"Polizzi","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ane.12261","article-title":"Glucocorticoids in myasthenia gravis \u2013 if, when, how, and how much?","volume":"130","author":"Hoffmann","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2017.10.037_bb0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1515\/CCLM.2004.065","article-title":"Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders","volume":"42","author":"Omwandho","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jns.2017.10.037_bb0140","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/rheumatology\/ken046","article-title":"Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion","volume":"47","author":"Perricone","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.jns.2017.10.037_bb0145","first-page":"309","article-title":"Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?","volume":"122","author":"Elovaara","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2017.10.037_bb0150","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.anai.2012.04.014","article-title":"Common variable immune deficiency and treatment with intravenous immunoglobulin during pregnancy","volume":"108","author":"Brinker","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jns.2017.10.037_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0160","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.880160504","article-title":"Single fiber electromyography in myasthenia gravis during pregnancy","volume":"16","author":"Massey","year":"1993","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2017.10.037_bb0165","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajmg.a.35223","article-title":"Teratogenecity of mycophenolate confirmed in a prospective study of the European network of teratology information services","volume":"158A","author":"Hoeltzenbein","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.jns.2017.10.037_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmg.2016.09.014","article-title":"Mycophenolate mofetil embryopathy: a newly recognized teratogenic syndrome","volume":"60","author":"Perez-Aytes","year":"2017","journal-title":"Eur. J. Med. Genet."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2017.10.037_bb0175","doi-asserted-by":"crossref","first-page":"S299","DOI":"10.1111\/j.1432-2277.2000.tb02043.x","article-title":"Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus","volume":"13","author":"Kainz","year":"2000","journal-title":"Transpl. Int."},{"key":"10.1016\/j.jns.2017.10.037_bb0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","article-title":"Immunosuppressive drugs and fertility","volume":"10","author":"Leroy","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2017.10.037_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.yrtph.2016.03.010","article-title":"Investigation of developmental toxicity and teratogenicity of cyclosporine a, tacrolimus and their combinations with prednisolone","volume":"77","author":"Unver Dogan","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jns.2017.10.037_bb0190","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/tera.10043","article-title":"Teratogen update: azathioprine and 6-mercaptopurine","volume":"65","author":"Polifka","year":"2002","journal-title":"Teratology"},{"key":"10.1016\/j.jns.2017.10.037_bb0195","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/bdra.20399","article-title":"Pregnancy outcome of women exposed to azathioprine during pregnancy","volume":"79","author":"Goldstein","year":"2007","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"key":"10.1016\/j.jns.2017.10.037_bb0200","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0000000000000054","article-title":"Non-steroidal anti-inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy","volume":"26","author":"Bermas","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jns.2017.10.037_bb0205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U","article-title":"Maternal corticosteroid use and risk of selected congenital anomalies","volume":"86","author":"Carmichael","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.jns.2017.10.037_bb0210","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0215","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0220","author":"US Food and Drug Administration Home Page"},{"key":"10.1016\/j.jns.2017.10.037_bb0225","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1542\/peds.2013-1985","article-title":"The transfer of drugs and therapeutics into human breast milk: an update on selected topics","volume":"132","author":"H.C. Sachs; Committee on drugs","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jns.2017.10.037_bb0235","series-title":"13th International Conference on Myasthenia Gravis and Related Disorders, New York","article-title":"Pregnancy outcome in women with myasthenia","author":"Lee","year":"2017"},{"key":"10.1016\/j.jns.2017.10.037_bb0240","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","article-title":"Immunoglobulin treatment in refractory myasthenia gravis","volume":"23","author":"Achiron","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2017.10.037_bb0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","article-title":"The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis","volume":"24","author":"Hilkevich","year":"2001","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2017.10.037_bb0250","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0303-8467(02)00017-3","article-title":"Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis","volume":"105","author":"Wegner","year":"2002","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2017.10.037_bb0255","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0260","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/mus.24259","article-title":"Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation","volume":"50","author":"Eienbr\u00f6ker","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2017.10.037_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2017.10.037_bb0270","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2017.10.037_bb0275","first-page":"294","article-title":"Use of Gammaglobulin to lower elevated natural killer cells in patients with recurrent miscarriage","volume":"60","author":"Cohen","year":"2015","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.jns.2017.10.037_bb0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0002-9378(97)80043-9","article-title":"Clinical uses of intravenous immunoglobulin in pregnancy","volume":"176","author":"Clark","year":"1997","journal-title":"Am. J. Obstet. Gyncecol."},{"key":"10.1016\/j.jns.2017.10.037_bb0285","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1600-0897.2012.01111.x","article-title":"Does immunotherapy for treatment of reproductive failure enhance live births?","volume":"67","author":"Coulam","year":"2012","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.jns.2017.10.037_bb0290","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ncn3.12079","article-title":"Successful early treatment with intravenous immunoglobulin for seronegative myasthenia gravis with onset during pregnancy: a case report","volume":"4","author":"Horiuchi","year":"2016","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.jns.2017.10.037_bb0295","first-page":"91","article-title":"Overcoming recurrent spontaneous abortions in women suffering from IgG subclass deficiency: high efficiency of low dose intravenous immunoglobulins treatment","volume":"47","author":"Manfredi","year":"2015","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"10.1016\/j.jns.2017.10.037_bb0300","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10067-004-0932-5","article-title":"Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin","volume":"23","author":"Bellisai","year":"2004","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jns.2017.10.037_bb0305","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/s10165-008-0020-9","article-title":"Successful treatment of new onset Wegener's granulomatosis with IVIG (intravenous immunoglobulin) during pregnancy: a case report","volume":"18","author":"Kim","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jns.2017.10.037_bb0310","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2310\/7750.2009.09001","article-title":"Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: case report and literature review","volume":"14","author":"Doiron","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.jns.2017.10.037_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2015.02.038","article-title":"Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis","volume":"26","author":"Nguyen","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jns.2017.10.037_bb0320","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0029-1145261","article-title":"Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study","volume":"34","author":"Heilmann","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jns.2017.10.037_bb0325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jri.2016.03.004","article-title":"Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study","volume":"115","author":"Ruffatti","year":"2016","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.jns.2017.10.037_bb0330","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000202171","article-title":"Antenatal intravenous immunoglobulin in chronic immune thrombocytopenic purpura: case report and literature review","volume":"25","author":"Howman","year":"2009","journal-title":"Fetal Diagn. Ther."},{"key":"10.1016\/j.jns.2017.10.037_bb0335","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/pd.2779","article-title":"Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions","volume":"31","author":"Kamphuis","year":"2011","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.jns.2017.10.037_bb0340","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00296-009-1166-2","article-title":"Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis","volume":"31","author":"Linardaki","year":"2011","journal-title":"Rheumatol. Int."},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2017.10.037_bb0345","first-page":"iii16","article-title":"Pregnancy in systemic sclerosis","volume":"47","author":"Miniati","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.jns.2017.10.037_bb0350","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","article-title":"Multiple sclerosis and pregnancy in the 'treatment era'","volume":"11","author":"Vukusic","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0355","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/j.1447-0756.2011.01680.x","article-title":"Prenatal high-dose immunoglobulin treatment for neonatal hemochromatosis: a case report and review of the literature","volume":"37","author":"Tanaka","year":"2011","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.jns.2017.10.037_bb0360","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jacc.2010.09.044","article-title":"Use of intravenous gamma globulin and corticosteroids in the treatment of maternal autoantibody-mediated cardiomyopathy","volume":"57","author":"Trucco","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2017.10.037_bb0365","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.fertnstert.2007.07.1387","article-title":"Assisted reproduction treatment in severe myasthenia gravis","volume":"90","author":"Ricci","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jns.2017.10.037_bb0370","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/humrep\/der227","article-title":"A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories","volume":"26","author":"Ensom","year":"2011","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.jns.2017.10.037_bb0375","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","article-title":"Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis","volume":"251","author":"Achiron","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2017.10.037_bb0380","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-0033-1349888","article-title":"Prenatal immunomodulation treatment in neonatal myasthenia gravis","volume":"217","author":"Welker","year":"2013","journal-title":"Z Geburstshilfe Neonatol."},{"key":"10.1016\/j.jns.2017.10.037_bb0385","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1749-6632.1976.tb47717.x","article-title":"Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management","volume":"274","author":"Brunner","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2017.10.037_bb0390","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0303-8467(87)80046-X","article-title":"Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis","volume":"89","author":"Scherpbier","year":"1987","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2017.10.037_bb0395","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1212\/WNL.41.6.919","article-title":"Factors influencing outcome of prednisone dose reduction in myasthenia gravis","volume":"41","author":"Miano","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2017.10.037_bb0400","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2017.10.037_bb0405","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.0000000000002405","article-title":"Myasthenia gravis exacerbation after discontinuing mycophenolate: a single-center cohort study","volume":"86","author":"Oskarsson","year":"2016","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17344180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X17344180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T06:52:09Z","timestamp":1530600729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X17344180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":80,"alternative-id":["S0022510X17344180"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2017.10.037","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous immunoglobulin as monotherapy for myasthenia gravis during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2017.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}